Cytosorbents Corporation (CTSO)
NASDAQ: CTSOHealthcareMedical DevicesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CTSO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.75M
- EPS (TTM)
- -$5.80
- Dividend yield
- None
- 52-week range
- 3.66 – 19.72
- Day range
- 3.67 – 3.81
- Volume / Avg
- 10.83K / 12.45K
- Beta
- —
- Shares outstanding
- 3.15M
52-week range
CTSO stock today
Shares of Cytosorbents (CTSO) finished lower on Oct 8 at $3.73, a drop of 3.62% or $0.14 per share, versus the S&P 500's 0.47% decline. Shares are 81.1% below their 52-week high of $19.72 and 1.9% above the 52-week low of $3.66, near the bottom of the past year's range. CTSO is down 70.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 80.9%.
Cytosorbents has posted a net loss over the last twelve months (EPS of -$5.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cytosorbents
Company profileCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Dr. Phillip P. Chan M.D., Ph.D.
- Headquarters
- Princeton, NJ
- Employees
- 129
- Website
- cytosorbents.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$47.50+1173.46%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Cytosorbents peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PLSMPulsenmore Ltd. | 1.92 | +0.73% | $12.49M | vs CTSO |
| NMTCNeuroOne Medical Technologies Corporation | 1.08 | -2.70% | $9.83M | vs CTSO |
| AEMDAethlon Medical Inc. | 6.01 | -0.99% | $9.64M | vs CTSO |
| SINTSiNtx Technologies Inc. | 2.11 | -2.77% | $14.06M | vs CTSO |
| TNONTenon Medical Inc. | 3.44 | -1.71% | $9.25M | vs CTSO |
| HSCSHeartSciences Inc. | 3.04 | -12.89% | $14.73M | vs CTSO |
| BMRABiomerica Inc. | 1.89 | -0.53% | $8.69M | vs CTSO |
| IRIXIRIDEX Corporation | 0.898 | +2.24% | $15.77M | vs CTSO |
Indexes, lists and sector
Appears in lists
Cytosorbents stock FAQ
What is Cytosorbents's stock price today?
CTSO last traded at $3.73 as of Oct 8, 4:00 PM EDT, down 3.62% on the day. Prices are delayed at least 15 minutes.
Does Cytosorbents pay a dividend?
No. Cytosorbents does not currently pay a regular cash dividend.
Who is Cytosorbents's CEO?
Dr. Phillip P. Chan M.D., Ph.D. is the chief executive officer of Cytosorbents Corporation, which has about 129 employees.
Has CTSO ever split its stock?
Yes. The most recent CTSO stock split was a 1-for-20 split on Sep 8, 2026, one of 2 splits on record.
What is the CTSO 52-week high?
The 52-week high for CTSO is $19.72 and the 52-week low is $3.66. The stock is currently 81.1% below its high.